Controversies in Drug Allergy: Beta-Lactam Hypersensitivity Testing

AAAAI/WAO 2018 Symposium Penicillin and Cephalosporin Allergy Testing Working Group

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

All beta-lactam use is associated with a certain rate of adverse reactions. Many of these adverse reactions result in an allergy to the beta-lactam being entered into the patient's medical record. Unfortunately, only a small minority of these recorded allergies are clinically significant immunologically mediated drug hypersensitivity. An unconfirmed allergy to beta-lactams is a significant public health risk, because patients so labeled typically do not receive narrow-spectrum penicillins and cephalosporins when clinically indicated. The alternative antibiotics they receive result in poorer clinical outcomes, increased incidence of serious antibiotic-resistant infections, prolonged hospitalizations, and greater health care utilization. There is a wide variation in beta-lactam allergy incidence and prevalence around the world, based in part on the specific beta-lactams used and overused. There is a wide variation in specific protocols used to confirm current tolerance of beta-lactams and remove these inaccurate allergy reports. Harmonizing testing protocols, when possible, may lead to more widespread use of narrow-spectrum beta-lactams, when clinically indicated, and improve patient safety worldwide. Further research is needed to better understand the regional differences in reporting beta-lactam allergy as this relates to regional differences in beta-lactam use and overuse, the frequency of clinically significant immunologically mediated beta-lactam hypersensitivity, and the optimal testing strategies to confirm current tolerance, based on presenting clinical symptoms.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology: In Practice
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Drug Hypersensitivity
beta-Lactams
Hypersensitivity
Patient Acceptance of Health Care
Anti-Bacterial Agents
Incidence
Cephalosporins
Patient Safety
Penicillins
Medical Records
Hospitalization
Public Health

Keywords

  • Allergy
  • Beta-lactam
  • Cephalosporin
  • Challenge
  • Drug provocation test
  • Hypersensitivity
  • IgE
  • Penicillin
  • Severe cutaneous adverse reaction
  • Skin test
  • T cell

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Controversies in Drug Allergy : Beta-Lactam Hypersensitivity Testing. / AAAAI/WAO 2018 Symposium Penicillin and Cephalosporin Allergy Testing Working Group.

In: Journal of Allergy and Clinical Immunology: In Practice, 01.01.2018.

Research output: Contribution to journalArticle

AAAAI/WAO 2018 Symposium Penicillin and Cephalosporin Allergy Testing Working Group. / Controversies in Drug Allergy : Beta-Lactam Hypersensitivity Testing. In: Journal of Allergy and Clinical Immunology: In Practice. 2018.
@article{d74941a00ad848dda4dab8e1eadea61a,
title = "Controversies in Drug Allergy: Beta-Lactam Hypersensitivity Testing",
abstract = "All beta-lactam use is associated with a certain rate of adverse reactions. Many of these adverse reactions result in an allergy to the beta-lactam being entered into the patient's medical record. Unfortunately, only a small minority of these recorded allergies are clinically significant immunologically mediated drug hypersensitivity. An unconfirmed allergy to beta-lactams is a significant public health risk, because patients so labeled typically do not receive narrow-spectrum penicillins and cephalosporins when clinically indicated. The alternative antibiotics they receive result in poorer clinical outcomes, increased incidence of serious antibiotic-resistant infections, prolonged hospitalizations, and greater health care utilization. There is a wide variation in beta-lactam allergy incidence and prevalence around the world, based in part on the specific beta-lactams used and overused. There is a wide variation in specific protocols used to confirm current tolerance of beta-lactams and remove these inaccurate allergy reports. Harmonizing testing protocols, when possible, may lead to more widespread use of narrow-spectrum beta-lactams, when clinically indicated, and improve patient safety worldwide. Further research is needed to better understand the regional differences in reporting beta-lactam allergy as this relates to regional differences in beta-lactam use and overuse, the frequency of clinically significant immunologically mediated beta-lactam hypersensitivity, and the optimal testing strategies to confirm current tolerance, based on presenting clinical symptoms.",
keywords = "Allergy, Beta-lactam, Cephalosporin, Challenge, Drug provocation test, Hypersensitivity, IgE, Penicillin, Severe cutaneous adverse reaction, Skin test, T cell",
author = "{AAAAI/WAO 2018 Symposium Penicillin and Cephalosporin Allergy Testing Working Group} and Torres, {Maria J.} and Adkinson, {N. Franklin} and Caubet, {Jean Christoph} and Khan, {David A.} and Kidon, {Mona I.} and Louis Mendelson and Gomes, {Eva Rebelo} and Ticha Rerkpattanapipat and Shuchen Zhang and Eric Macy",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jaip.2018.07.051",
language = "English (US)",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",

}

TY - JOUR

T1 - Controversies in Drug Allergy

T2 - Beta-Lactam Hypersensitivity Testing

AU - AAAAI/WAO 2018 Symposium Penicillin and Cephalosporin Allergy Testing Working Group

AU - Torres, Maria J.

AU - Adkinson, N. Franklin

AU - Caubet, Jean Christoph

AU - Khan, David A.

AU - Kidon, Mona I.

AU - Mendelson, Louis

AU - Gomes, Eva Rebelo

AU - Rerkpattanapipat, Ticha

AU - Zhang, Shuchen

AU - Macy, Eric

PY - 2018/1/1

Y1 - 2018/1/1

N2 - All beta-lactam use is associated with a certain rate of adverse reactions. Many of these adverse reactions result in an allergy to the beta-lactam being entered into the patient's medical record. Unfortunately, only a small minority of these recorded allergies are clinically significant immunologically mediated drug hypersensitivity. An unconfirmed allergy to beta-lactams is a significant public health risk, because patients so labeled typically do not receive narrow-spectrum penicillins and cephalosporins when clinically indicated. The alternative antibiotics they receive result in poorer clinical outcomes, increased incidence of serious antibiotic-resistant infections, prolonged hospitalizations, and greater health care utilization. There is a wide variation in beta-lactam allergy incidence and prevalence around the world, based in part on the specific beta-lactams used and overused. There is a wide variation in specific protocols used to confirm current tolerance of beta-lactams and remove these inaccurate allergy reports. Harmonizing testing protocols, when possible, may lead to more widespread use of narrow-spectrum beta-lactams, when clinically indicated, and improve patient safety worldwide. Further research is needed to better understand the regional differences in reporting beta-lactam allergy as this relates to regional differences in beta-lactam use and overuse, the frequency of clinically significant immunologically mediated beta-lactam hypersensitivity, and the optimal testing strategies to confirm current tolerance, based on presenting clinical symptoms.

AB - All beta-lactam use is associated with a certain rate of adverse reactions. Many of these adverse reactions result in an allergy to the beta-lactam being entered into the patient's medical record. Unfortunately, only a small minority of these recorded allergies are clinically significant immunologically mediated drug hypersensitivity. An unconfirmed allergy to beta-lactams is a significant public health risk, because patients so labeled typically do not receive narrow-spectrum penicillins and cephalosporins when clinically indicated. The alternative antibiotics they receive result in poorer clinical outcomes, increased incidence of serious antibiotic-resistant infections, prolonged hospitalizations, and greater health care utilization. There is a wide variation in beta-lactam allergy incidence and prevalence around the world, based in part on the specific beta-lactams used and overused. There is a wide variation in specific protocols used to confirm current tolerance of beta-lactams and remove these inaccurate allergy reports. Harmonizing testing protocols, when possible, may lead to more widespread use of narrow-spectrum beta-lactams, when clinically indicated, and improve patient safety worldwide. Further research is needed to better understand the regional differences in reporting beta-lactam allergy as this relates to regional differences in beta-lactam use and overuse, the frequency of clinically significant immunologically mediated beta-lactam hypersensitivity, and the optimal testing strategies to confirm current tolerance, based on presenting clinical symptoms.

KW - Allergy

KW - Beta-lactam

KW - Cephalosporin

KW - Challenge

KW - Drug provocation test

KW - Hypersensitivity

KW - IgE

KW - Penicillin

KW - Severe cutaneous adverse reaction

KW - Skin test

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=85053733875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053733875&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2018.07.051

DO - 10.1016/j.jaip.2018.07.051

M3 - Article

C2 - 30245291

AN - SCOPUS:85053733875

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

ER -